Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205 trial. We present updated results (median follow-up, ∼5 years). P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansell, Stephen M., Bröckelmann, Paul J., von Keudell, Gottfried, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Collins, Graham P., Cohen, Jonathon B., de Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trněný, Marek, Provencio, Mariano, Jäger, Ulrich, Willenbacher, Wolfgang, Wen, Rachael, Akyol, Alev, Mikita-Geoffroy, Joanna, Shipp, Margaret A., Engert, Andreas, Armand, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589773/
https://www.ncbi.nlm.nih.gov/pubmed/37530622
http://dx.doi.org/10.1182/bloodadvances.2023010334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589773/
https://www.ncbi.nlm.nih.gov/pubmed/37530622
http://dx.doi.org/10.1182/bloodadvances.2023010334

Ejemplares similares